E M Lewiecki

Summary

Publications

  1. ncbi Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    IDrugs 12:799-809. 2009
  2. pmc Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:227-35. 2013
  3. doi Proceedings of the 2011 Santa Fe Bone symposium
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    J Clin Densitom 15:1-20. 2012
  4. doi Tumor-induced osteomalacia: lessons learned
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Arthritis Rheum 58:773-7. 2008
  5. doi Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 11:313-24. 2008
  6. doi Managing osteoporosis: challenges and strategies
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Cleve Clin J Med 76:457-66. 2009
  7. ncbi Renal safety of intravenous bisphosphonates in the treatment of osteoporosis
    E Michael Lewiecki
    University of New Mexico School of Medicine, Albuquerque, New Mexico, USA
    Expert Opin Drug Saf 6:663-72. 2007
  8. ncbi Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, New Mexico 87106, USA
    Expert Opin Investig Drugs 16:1663-72. 2007
  9. ncbi Denosumab: a promising drug for the prevention and treatment of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Womens Health (Lond Engl) 2:517-25. 2006
  10. doi Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, University of New Mexico School of Medicine, Albuquerque, New Mexico 87106, USA
    J Womens Health (Larchmt) 18:1615-26. 2009

Detail Information

Publications101 found, 100 shown here

  1. ncbi Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    IDrugs 12:799-809. 2009
    ..Odanacatib is a promising agent for the management of postmenopausal osteoporosis and other skeletal disorders associated with excessive bone remodeling...
  2. pmc Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
    M R McClung
    Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 626, Portland, OR 97213, USA
    Osteoporos Int 24:227-35. 2013
    ..Denosumab treatment was well tolerated throughout the 8-year study...
  3. doi Proceedings of the 2011 Santa Fe Bone symposium
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    J Clin Densitom 15:1-20. 2012
    ....
  4. doi Tumor-induced osteomalacia: lessons learned
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Arthritis Rheum 58:773-7. 2008
    ..The metabolic abnormalities may be partially or completely corrected with phosphate supplementation and calcitriol. A definitive diagnosis and treatment require excision of the responsible tumor...
  5. doi Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 11:313-24. 2008
    ..Presented here are short essays based on the key clinical presentations of the 2007 Santa Fe Bone Symposium...
  6. doi Managing osteoporosis: challenges and strategies
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Cleve Clin J Med 76:457-66. 2009
    ..This paper is a review of unmet needs in the management of osteoporosis and strategies to improve clinical outcomes...
  7. ncbi Renal safety of intravenous bisphosphonates in the treatment of osteoporosis
    E Michael Lewiecki
    University of New Mexico School of Medicine, Albuquerque, New Mexico, USA
    Expert Opin Drug Saf 6:663-72. 2007
    ..Due to lack of data, no conclusions can be made regarding bisphosphonate safety in patients with intrinsic renal disease or an estimated glomerular filtration rate of < 30 ml/min...
  8. ncbi Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, New Mexico 87106, USA
    Expert Opin Investig Drugs 16:1663-72. 2007
    ..Bazedoxifene/conjugated estrogens is a potential agent for the prevention of PMO and control of menopausal symptoms...
  9. ncbi Denosumab: a promising drug for the prevention and treatment of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Womens Health (Lond Engl) 2:517-25. 2006
    ..Denosumab is well tolerated with adverse events similar to placebo. Denosumab is a promising investigational agent for the management of osteoporosis and other diseases associated with bone loss...
  10. doi Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, University of New Mexico School of Medicine, Albuquerque, New Mexico 87106, USA
    J Womens Health (Larchmt) 18:1615-26. 2009
    ..Clinical investigation of these promising new agents is ongoing to evaluate efficacy and safety, with the goal of developing effective strategies to maximize long-term tolerance, compliance, and persistence with therapy...
  11. ncbi Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Bone Miner Res 22:1832-41. 2007
    ..Continued study of denosumab is warranted in the treatment of low BMD in postmenopausal women...
  12. doi Denosumab--an emerging treatment for postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, New Mexico 87106, USA
    Expert Opin Biol Ther 10:467-76. 2010
    ..Denosumab is an investigational fully human monoclonal antibody to receptor activator of NF-kappaB ligand (RANKL), a cytokine member of the TNF family that is the principal mediator of osteoclastic bone resorption...
  13. doi Monitoring pharmacological therapy for osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Rev Endocr Metab Disord 11:261-73. 2010
    ..It is therefore necessary to monitor therapy with biomarkers such as bone mineral density and bone turnover markers. This is a review of the utility of these tools in the care of individual patients...
  14. doi 2009 Santa Fe Bone symposium
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    J Clin Densitom 13:1-9. 2010
    ..Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium...
  15. doi Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    South Med J 101:735-9. 2008
    ..This report describes the methodology and presents the results of this PDC. The first ISCD Pediatric PDC was held June 20 to 21, 2007 in Montreal, Quebec, Canada, and is reported separately...
  16. ncbi Redefining osteoporosis treatment: Who to treat and how long to treat
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    Arq Bras Endocrinol Metabol 50:694-704. 2006
    ..Patients at high risk for fracture should be considered for pharmacological therapy, which can reduce fracture risk by about 50%...
  17. doi Treatment of osteoporosis with denosumab
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Maturitas 66:182-6. 2010
    ..It may be particularly useful in clinical practice for the treatment of patients with gastrointestinal contraindications or side effects with oral bisphosphonates and for patients with malabsorption...
  18. ncbi Intravenous zoledronic acid for the treatment of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Curr Osteoporos Rep 6:17-23. 2008
    ..Zoledronic acid has the potential to improve clinical outcomes by reducing the risk of fracture in patients with osteoporosis...
  19. ncbi Emerging drugs for postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, New Mexico 87106, USA
    Expert Opin Emerg Drugs 14:129-44. 2009
    ..These new therapeutic agents, new delivery systems, and new methods of combining drugs may ultimately reduce the great personal and economic burden of osteoporotic fractures...
  20. doi New guidelines for the prevention and treatment of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    South Med J 102:175-9. 2009
    ..Good clinical judgment should be the ultimate determinant of treatment decisions. We anticipate that further refinements to FRAX and subsequent updates of the NOF guide will improve their clinical utility...
  21. doi Common mistakes in the clinical use of bone mineral density testing
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, University of New Mexico School of Medicine, Albuquerque, NM 87106, USA
    Nat Clin Pract Rheumatol 4:667-74. 2008
    ..This Review describes and discusses the mistakes commonly made in BMD testing, and emphasizes the importance of maintaining high-quality standards in order to optimize patient management...
  22. doi Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, New Mexico 87106, USA
    J Clin Endocrinol Metab 94:171-80. 2009
    ....
  23. doi International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Bone 43:1115-21. 2008
    ..Those recommendations that were approved by the ISCD Board of Directors become Official Positions. This is a review of the methodology of the PDCs and selected ISCD Official Positions...
  24. doi Osteoporosis care at risk in the United States
    E M Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Osteoporos Int 19:1505-9. 2008
    ....
  25. doi A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 11:478-84. 2008
    ..This is a review of the clinical trial data supporting the use of IV ZOL to reduce fracture risk, and its potential role in the management of PMO in clinical practice...
  26. ncbi Vertebroplasty and kyphoplasty update
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Curr Osteoporos Rep 6:114-9. 2008
    ..Although these procedures hold great promise in the management of vertebral fractures, many questions about long-term efficacy and safety remain...
  27. doi Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry
    E M Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Osteoporos Int 19:1369-78. 2008
    ..The most recent Adult PDC was held 20-22 July 2007, in Lansdowne, VA, USA. This Special Report summarizes the methodology of the ISCD PDCs and presents selected Official Positions of general interest...
  28. doi Denosumab update
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    Curr Opin Rheumatol 21:369-73. 2009
    ..This is a review of recent clinical data on the efficacy and safety of denosumab for the treatment of postmenopausal osteoporosis and rheumatoid arthritis...
  29. doi Assessing response to osteoporosis therapy
    E M Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Osteoporos Int 19:1363-8. 2008
    ....
  30. ncbi Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    Clin Ther 30:605-21. 2008
    ..Gastrointestinal (GI) symptoms and high dosing frequency have been cited as reasons for inadequate adherence to daily or weekly oral bisphosphonate therapy. Inadequate adherence may lead to poor therapeutic outcomes...
  31. doi Prevention and treatment of postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Obstet Gynecol Clin North Am 35:301-15, ix. 2008
    ..Patients at risk for osteoporosis can be diagnosed with a simple bone density test before the first fracture occurs. Pharmacologic agents for patients at high risk for fracture can reduce the burden of osteoporotic fractures...
  32. doi 2008 Santa Fe Bone Symposium: update on osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 12:135-57. 2009
    ..This is a collection of scientific essays based on presentations and discussions at the 2008 Santa Fe Bone Symposium...
  33. doi Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street Northeast, Albuquerque, NM 87106
    Endocr Pract 15:573-9. 2009
    ..To evaluate the benefits and limitations of randomized controlled trials (RCTs), clinical practice guidelines (CPGs), and clinical judgment in the management of osteoporosis...
  34. doi The official positions of the International Society for Clinical Densitometry: perceptions and commentary
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 12:267-71. 2009
    ..This is a review of the benefits and limitations of the ISCD OPs with emphasis on areas of controversy...
  35. ncbi Bone density testing in clinical practice
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    Arq Bras Endocrinol Metabol 50:586-95. 2006
    ..Standardized methodologies are being developed to establish cost-effective intervention thresholds for pharmacological therapy based on T-score combined with clinical risk factors for fracture...
  36. ncbi DXA quality matters
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 9:388-92. 2006
    ..We also suggest that they provide demonstration of proficiency in bone densitometry in order to assure patients, referring healthcare providers, and payers of medical services that these skills have been acquired and maintained...
  37. doi Safety of long-term bisphosphonate therapy for the management of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    Drugs 71:791-814. 2011
    ..When making the decision to use a bisphosphonate for the treatment of osteoporosis, the balance between benefit and potential risks according to clinical circumstances of each patient should be considered...
  38. ncbi Clinical applications of bone density testing for osteoporosis
    E M Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Minerva Med 96:317-30. 2005
    ..Clinical applications of BMD testing are presented in this review...
  39. ncbi Review of guidelines for bone mineral density testing and treatment of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Curr Osteoporos Rep 3:75-83. 2005
    ....
  40. doi The role of risk communication in the care of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Curr Osteoporos Rep 9:141-8. 2011
    ....
  41. ncbi Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    J Clin Densitom 8:143-4. 2005
  42. doi Risk communication and shared decision making in the care of patients with osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 13:335-45. 2010
    ....
  43. ncbi Premenopausal bone health assessment
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Curr Rheumatol Rep 7:46-52. 2005
    ..Premenopausal women with fractures are at increased risk for postmenopausal osteoporosis and fractures later in life...
  44. doi FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    J Clin Densitom 14:223-5. 2011
    ..The evidence and recommendations were presented to a panel of experts at the ISCD-IOF FRAX(®) Position Development Conference, resulting in the development of ISCD-IOF Official Positions addressing FRAX(®)-related issues...
  45. ncbi Official positions of the international society for clinical densitometry
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    J Clin Endocrinol Metab 89:3651-5. 2004
    ..Recommendations that are accepted become the Official Positions of the ISCD. This Special Report summarizes the methodology of the ISCD Position Development Conferences and presents selected Official Positions of general interest...
  46. ncbi Special report on the official positions of the International Society for Clinical Densitometry
    E M Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Osteoporos Int 15:779-84. 2004
    ..Recommendations that are accepted become the Official Positions of the ISCD. This Special Report summarizes the methodology of the ISCD PDCs and presents selected Official Positions of general interest...
  47. ncbi Low bone mineral density in premenopausal women
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Inc, Albuquerque, NM 87106, USA
    South Med J 97:544-50. 2004
    ..Premenopausal women with fractures are at increased risk for fractures later in life. Methods for evaluating these patients and selecting those who require additional care are reviewed...
  48. doi Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    J Clin Densitom 14:226-36. 2011
    ..The evidence and recommendations were presented to a panel of experts at the Joint ISCD-IOF FRAX® Position Development Conference, resulting in the development of Joint ISCD-IOF Official Positions addressing FRAX®-related issues...
  49. doi New targets for intervention in the treatment of postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Nat Rev Rheumatol 7:631-8. 2011
    ..These and other novel interventions that target newly recognized regulators of bone remodeling are promising agents for the treatment of osteoporosis...
  50. ncbi Nonresponders to osteoporosis therapy
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Inc, 300 Oak St NE, Albuquerque, NM 87106, USA
    J Clin Densitom 6:307-14. 2003
    ..The proposed definition of nonresponse identifies a subset of patients who may require a change of therapy and/or additional medical intervention. More data are needed to develop guidelines for clinicians. Further study is suggested...
  51. ncbi Denosumab for joints and bones
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Curr Rheumatol Rep 11:196-201. 2009
    ..It is generally well tolerated, with a good safety profile. Adverse and serious adverse events, including infections and malignancy, are similar in patients treated with denosumab or placebo...
  52. ncbi Update on bone density testing
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Curr Osteoporos Rep 3:136-42. 2005
    ..Standardized methodologies are being developed to establish intervention thresholds for pharmacologic therapy based on T-score combined with clinical risk factors for fracture...
  53. doi Osteoporosis update from the 2010 santa fe bone symposium
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 14:1-21. 2011
    ..The key messages from each presentation, including the best available medical evidence and potential current and future clinical applications, are provided here...
  54. ncbi Long dosing intervals in the treatment of postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Curr Med Res Opin 23:2617-25. 2007
    ..Nevertheless, osteoporosis is underdiagnosed and undertreated. Even among those who are diagnosed and treated, widespread nonadherence with treatment regimens undermines the efficacy of osteoporosis therapy...
  55. doi Bone densitometry and vertebral fracture assessment
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Curr Osteoporos Rep 8:123-30. 2010
    ..Optimal performance of DXA and VFA requires training and adherence to quality standards...
  56. doi Management of skeletal health in patients with asymptomatic primary hyperparathyroidism
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Clin Densitom 13:324-34. 2010
    ..It is not known whether any medical intervention reduces fracture risk in patients with PHPT. There are insufficient data on the natural history and treatment of normocalcemic PHPT to make recommendations for management of this disorder...
  57. doi Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak Street NE, Albuquerque, NM 87106, USA
    Curr Osteoporos Rep 8:15-22. 2010
    ..This article reviews the clinical use and abuse of the two biomarkers most commonly used to assess the effectiveness of therapy in clinical practice: bone mineral density testing and measurement of markers of bone turnover...
  58. ncbi Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    J Clin Endocrinol Metab 91:4215-22. 2006
    ..Knowledge of VFs may change diagnostic classification, estimation of future fracture risk, and clinical management. VF assessment (VFA) by dual-energy x-ray absorptiometry is a method for imaging the spine to diagnose VFs...
  59. doi Clinical use of denosumab for the treatment for postmenopausal osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Curr Med Res Opin 26:2807-12. 2010
    ..Denosumab is a new therapeutic option to reduce fracture risk in women with postmenopausal osteoporosis, especially for those with impaired renal function or with intolerance or poor response to oral therapy...
  60. doi Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    Expert Opin Biol Ther 11:117-27. 2011
    ....
  61. ncbi RANK ligand inhibition with denosumab for the management of osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, New Mexico 87106, USA
    Expert Opin Biol Ther 6:1041-50. 2006
    ..Denosumab has been shown to increase bone mineral density (BMD) and reduce bone turnover in postmenopausal women with low BMD. Denosumab is a potential treatment for osteoporosis and other skeletal disorders...
  62. doi Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials
    E M Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    Int J Clin Pract 64:821-6. 2010
    ....
  63. ncbi Assessment of osteoporosis-website quality
    E M Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, 300 Oak St NE, Albuquerque, NM 87106, USA
    Osteoporos Int 17:741-52. 2006
    ..The aim of this study was to develop and evaluate measurement tools to determine the quality of osteoporosis websites for patients...
  64. ncbi Uses and misuses of quantitative ultrasonography in managing osteoporosis
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM, USA
    Cleve Clin J Med 73:742-6, 749-52. 2006
    ..As more data become available, however, it may play a larger role. A thorough understanding of the utility and limitations of this test is necessary for using it effectively in clinical practice...
  65. ncbi Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children
    Aliya A Khan
    Divisions of Endocrinology and Geriatrics, McMaster University, Hamilton, ON, Canada
    J Clin Densitom 7:51-64. 2004
    ..Previously, this group addressed the performance of densitometry in postmenopausal women. This report addresses the use of densitometry in men, premenopausal women, and children with a focus on dual-energy X-ray absorptiometry...
  66. pmc The 2002 Canadian bone densitometry recommendations: take-home messages
    Aliya A Khan
    Division of Geriatrics, McMaster University, Hamilton, ON
    CMAJ 167:1141-5. 2002
  67. doi Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Blvd, Ste 250, Lakewood, CO 80227, USA
    Bone 43:222-9. 2008
    ..We assessed the long-term efficacy and safety of denosumab, and the effects of discontinuing and restarting denosumab treatment in postmenopausal women with low bone mass...
  68. ncbi Standards for performing DXA in individuals with secondary causes of osteoporosis
    Aliya A Khan
    Division of Endocrinology, McMaster University, Hamilton, Ontario, Canada, and Hanover General Hospital, PA, USA
    J Clin Densitom 9:47-57. 2006
    ..Dual-energy X-ray absorptiometry is a valuable tool in assessing skeletal health in individuals with secondary causes of osteoporosis...
  69. ncbi Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado, USA
    J Bone Miner Res 20:1315-22. 2005
    ..5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year...
  70. doi Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial
    Paul D Miller
    Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Ste 250, Lakewood, Colorado 80227, USA
    J Clin Endocrinol Metab 96:394-402. 2011
    ..This is a study extension to evaluate the efficacy and safety of long-term treatment with denosumab in postmenopausal women with low bone mass...
  71. ncbi Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    J Bone Miner Res 23:525-35. 2008
    ..Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD...
  72. ncbi Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis
    Peiqi Chen
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Bone Miner Res 20:962-70. 2005
    ..Early increases in the PICP and the PINP were the best predictors of BMD response to teriparatide in this analysis...
  73. ncbi Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass
    Robert R Recker
    Creighton University, Osteoporosis Research Center, 601 North 30th Street, Suite 5766, Omaha, NE 68131, USA
    Bone 40:843-51. 2007
    ..In summary, as this trial was terminated early, there was insufficient power to compare the fracture risks between alendronate and raloxifene. Safety profiles were as expected from clinical trial and post-marketing reports...
  74. ncbi Vertebral fracture assessment: the 2005 ISCD Official Positions
    Tamara Vokes
    Section of Endocrinology, University of Chicago, Chicago, IL 60637, and Metro West Medical Center, Framingham, MA, USA
    J Clin Densitom 9:37-46. 2006
    ..The ISCD Official Positions with respect to the above issues, as well as the rationale and evidence used to derive these positions, are presented here...
  75. ncbi Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference
    Neil Binkley
    University of Wisconsin, Madison, WI, USA
    J Clin Densitom 9:4-14. 2006
    ..This report describes the methodology of the 2005 PDC and presents a summary of all ISCD Official Positions...
  76. ncbi Augmentation procedures for osteoporotic vertebral fractures--an ongoing experiment or emerging standard of care?
    E Michael Lewiecki
    South Med J 99:449-50. 2006
  77. ncbi Skeletal health prognostications
    E Michael Lewiecki
    South Med J 99:105-6. 2006
  78. ncbi Denosumab in postmenopausal women with low bone mineral density
    Michael R McClung
    Providence Portland Medical Center, Portland, Oreg, USA
    N Engl J Med 354:821-31. 2006
    ..The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action...
  79. ncbi Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry
    Sanford Baim
    Rheumatic Disease Center, Glendale, Wisconsin, USA
    J Clin Densitom 8:371-8. 2005
    ..The patient-care benefits of precision assessment outweigh the risk of exposure to trivial doses of ionizing radiation...
  80. ncbi A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis
    Byron Cryer
    Division of Digestive Diseases, Dallas Veterans Affairs Medical Center, Dallas, Texas 75216, USA
    Am J Geriatr Pharmacother 3:127-36. 2005
    ..This study evaluated the overall safety and tolerability of once-weekly (OW) alendronate 70 mg oral solution (OS) versus OW placebo OS...
  81. ncbi Clinical use of serum and urine bone markers in the management of osteoporosis
    Apurva K Srivastava
    Musculoskeletal Disease Center, VA Loma Linda Healthcare System, and Department of Medicine, Loma Linda University, Loma Linda, CA 92357, USA
    Curr Med Res Opin 21:1015-26. 2005
    ..In this article, we provide a brief summary to primary practitioners about the role bone markers can play in the management of osteoporosis...
  82. ncbi Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence
    Neil Binkley
    University of Wisconsin Osteoporosis Clinical Center and Research Program, Madison, Wisconsin, USA
    J Bone Miner Res 20:195-201. 2005
    ..Use of a recalculated young-normal SD for the GE Lunar-adjusted NHANES III database improved diagnostic agreement and is recommended...
  83. ncbi Impact of using the ultradistal radius region of interest on diagnostic classification
    Gary M Kiebzak
    Center for Orthopaedic Research and Education, St Luke s Episcopal Hospital, 6720 Bertner Avenue, Houston, TX 77030, USA
    J Clin Densitom 7:143-52. 2004
    ..The group mean T-scores were lowest for the UDR compared to the spine and hip with GE Lunar but not Hologic patients...
  84. ncbi Official positions of the International Society for Clinical Densitometry
    Edward S Leib
    South Med J 97:107-10. 2004
  85. ncbi Official positions of the International Society for Clinical Densitometry
    Edward S Leib
    International Society for Clinical Densitometry International Society for Clinical Densitometry, West Hartford, CT 06117 2507, USA
    J Clin Densitom 7:1-6. 2004
    ....
  86. ncbi Official positions of the International Society for Clinical Densitometry
    E Michael Lewiecki
    Osteoporos Int 17:1700-1. 2006
  87. ncbi Is it ethical to use placebos in osteoporosis trials?
    Sergio Ragi-Eis
    Osteoporosis Diagnosis and Research Center of Espírito Santo, CEDOES, Vitoria ES, Brazil
    J Clin Densitom 9:274-80. 2006
    ..Delay in developing mutually acceptable models may impair scientific development in the field and possibly deprive patients of potentially beneficial treatments...
  88. ncbi Position Development Conference of the International Society for Clinical Densitometry. Vancouver, BC, July 15-17, 2005
    Edward S Leib
    University of Vermont Medicine, 111 Colchester Avenue, Burlington, VT 05401, USA
    J Rheumatol 33:2319-21. 2006
    ..The Official Positions reached at this conference enumerated in this report have been published in The Journal of Clinical Densitometry, and can be found at www.iscd.org...
  89. doi Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions
    Didier B Hans
    Geneva University Hospital, Geneva, Switzerland
    J Clin Densitom 11:188-206. 2008
    ....
  90. doi Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions
    Marc Antoine Krieg
    Lausanne University Hospital, Lausanne, Switzerland
    J Clin Densitom 11:163-87. 2008
    ..The ISCD Official Positions on QUS resulting from this PDC, the rationale for their establishment, and recommendations for further study are presented here...
  91. doi Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions
    Klaus Engelke
    Institute of Medical Physics, University of Erlangen, Germany Synarc, Hamburg, Germany
    J Clin Densitom 11:123-62. 2008
    ..Measurements at the hip may have clinical relevance, as this is an important fracture site; however, due to limited medical evidence, definitive advice on its use in clinical practice cannot be provided until more data emerge...
  92. doi Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference
    Sanford Baim
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Densitom 11:75-91. 2008
    ....
  93. ncbi An integrated approach: bisphosphonate management for the treatment of osteoporosis
    Gary Owens
    Am J Manag Care 13:S290-308; quiz S309-12. 2007
    ..This continuing education activity, based on a roundtable of managed care experts, explores new approaches for developing an effective bisphosphonate management policy for the treatment of osteoporosis...
  94. ncbi Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure
    Robert R Recker
    School of Medicine, Creighton University, Omaha, Nebraska 68131, USA
    J Bone Miner Res 23:6-16. 2008
    ..Zoledronic acid reduced bone turnover by 63% and preserved bone structure and volume, with evidence of ongoing bone remodeling in 99% of biopsies obtained...
  95. ncbi Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial
    Henry G Bone
    Michigan Bone and Mineral Clinic, 22201 Moross Road, Suite 260, Detroit, Michigan 48236 2175, USA
    J Clin Endocrinol Metab 92:4671-7. 2007
    ..Observational studies and secondary analyses from lipid-lowering trials have yielded inconsistent results regarding the effect of these agents on bone mineral density and fracture risk...
  96. ncbi Vertebral Fracture Assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A White Paper of the International Society for Clinical Densitometry
    Andrew J Laster
    Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC 28207, USA
    J Clin Densitom 10:227-38. 2007
    ..For health care providers regardless of their country, this article underscores the value of VFA as an alternative to spine radiography in the evaluation and management of postmenopausal women with suspected osteoporosis...
  97. ncbi A review of strontium ranelate and its effect on DXA scans
    Glen M Blake
    King s College London School of Medicine, London, UK
    J Clin Densitom 10:113-9. 2007
    ....
  98. ncbi Diagnostic agreement at the total hip using different DXA systems and the NHANES III database
    Gary M Kiebzak
    Center for Orthopaedic Research and Education, St Luke s Episcopal Hospital, Houston, TX 77025, USA
    J Clin Densitom 10:132-7. 2007
    ..11 vs 0.32 for lumbar spine (p less than 0.001). Use of the NHANES III standardized database results in good diagnostic agreement at total hip between Prodigy and Delphi...
  99. ncbi Summary of the International Society For Clinical Densitometry 2005 Position Development Conference
    Neil Binkley
    Department of Medicine, University of Wisconsin, Madison, WI 53705, USA
    J Bone Miner Res 22:643-5. 2007
  100. ncbi Peripheral bone densitometry: Clinical applications
    Sergio Ragi Eis
    CEDOES Centro de Diagnostico e Pesquisa, Vitoria, Brazil
    Arq Bras Endocrinol Metabol 50:596-602. 2006
    ..When central DXA testing is not available, peripheral BMD testing may be considered to identify individuals who might benefit from pharmacological intervention...
  101. ncbi Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study
    James A Simon
    George Washington University School of Medicine, Washington, DC, USA
    Clin Ther 24:1871-86. 2002
    ..Alendronate, an oral bisphosphonate, is available for the treatment of osteoporosis in a 70-mg once-weekly and a 10-mg once-daily formulation...